Knowledge of regulatory elements will point us toward new therapeutic approaches and expand the “druggable genome.” A specific example is the use of Farnesoid X receptor (FXR) agonists to augment the transcription of FXR-responsive genes such as

dimethylarginine dimethylaminohydrolase in portal hypertension, a target with no alternative pharmacological agonist.18 However, ENCODE also opens the door for targeted therapies to regulatory elements. Functional elements, including DNA sequences, transcription factors, and noncoding RNAs, have been widely considered “undruggable” targets, mostly because of the incomplete molecular understanding of these complex systems. However, as an example, microRNAs Sunitinib supplier (miRs) are ABT-263 cell line key RNA molecules regulating gene expression. Anti-miR oligonucleotide therapies directed to the liver have been shown to modulate cholesterol metabolism and hepatitis C viral kinetics, and phase 2 clinical studies are in progress.19 Thus, the paradigm shift in genomic data provided by ENCODE, along with improved chemistry for the

delivery of nucleic acid based therapies to the liver, has provided the opportunity for novel genome and epigenome targeted therapies. As William Ford Gibson famously said, “the future already exists, it’s just not very evenly distributed. “
“Chronic hepatitis C virus (HCV) infection can cause liver damage, ranging from mild to more severe conditions, such as fibrosis and cirrhosis.

Hepatic stellate cell (HSC) activation is a key event in HCV-induced liver fibrosis. HSCs express several HCV coreceptors that interact with HCV proteins, promoting liver fibrogenesis. In addition, HSCs have the ability to engulf apoptotic bodies of hepatocytes find more induced by HCV and trigger a profibrogenic response. Recent studies have suggested that HSCs may play a novel role in the liver innate immunity. HSCs enhanced differentiation and accumulation of regulatory T cells. HSCs-activated natural killer cells could produce γ-interferon that inhibits HCV replication. Importantly, HSCs possess functional Toll-like receptor-3 and retinoic acid-inducible gene I that can be activated by their ligands (poly I : C, 5′ppp-dsRNA), leading to the induction of interferon and inhibition of HCV replication in hepatocytes. These new observations highlight the importance of HSCs in liver immunity against HCV, which is the focus of this review paper. Because of the chronic nature of hepatitis C virus (HCV) infection and its high prevalence and significant morbidity of the resulting diseases, HCV is and will continue to be a serious global health threat for many years to come.[1] As a hepatitis virus, HCV infects human liver where the interactions between HCV and innate immunity play a key role in the immunopathogenesis of HCV disease. Unfortunately, the majority of HCV-infected subjects develop chronic infection that can result in liver fibrosis and cirrhosis.